<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Contraindications and precautions to diphtheria, tetanus, and pertussis-containing vaccines for children and adolescents age 7 through 18 years</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Contraindications and precautions to diphtheria, tetanus, and pertussis-containing vaccines for children and adolescents age 7 through 18 years</h1>
<div class="graphic"><div class="figure"><div class="ttl">Contraindications and precautions to diphtheria, tetanus, and pertussis-containing vaccines for children and adolescents age 7 through 18 years</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Vaccine</td> <td class="subtitle1">Contraindications</td> <td class="subtitle1">Precautions*</td> </tr> <tr> <td>Tdap</td> <td> <ul> <li>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component, including latex<sup>¶</sup> <ul> <li>Refer to an allergist to evaluate allergy to tetanus toxoid and possibility of desensitization to tetanus toxoid </li> </ul> </li> <li>Encephalopathy (eg, coma, decreased level of consciousness, or prolonged seizure) within 7 days of previous dose of DTwP, DTaP, or Tdap that is not attributable to another identifiable cause </li> </ul> </td> <td> <ul> <li>Guillain-Barré syndrome &lt;6 weeks after previous dose of tetanus toxoid-containing vaccine </li> <li>Progressive or unstable neurologic disorder, uncontrolled seizures, or progressive encephalopathy <ul> <li>Defer pertussis component until a treatment regimen has been established and the condition has stabilized</li> </ul> </li> <li>History of Arthus-type reaction after a previous dose of tetanus or diphtheria toxoid-containing vaccines <ul> <li>Defer vaccination until ≥10 years after the last dose of the tetanus toxoid-containing vaccine </li> </ul> </li> <li>Moderate or severe acute illness with or without fever </li> </ul> </td> </tr> <tr> <td>Td</td> <td> <ul> <li>Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component, including latex<sup>¶</sup> <ul> <li>Refer to an allergist to evaluate allergy to tetanus toxoid and possibility of desensitization to tetanus toxoid </li> </ul> </li> </ul> </td> <td> <ul> <li>Guillain-Barré syndrome &lt;6 weeks after previous dose of tetanus toxoid-containing vaccine </li> <li>History of Arthus-type reaction after a previous dose of tetanus or diphtheria toxoid-containing vaccines <ul> <li>Defer vaccination until ≥10 years after the last dose of the tetanus toxoid-containing vaccine </li> </ul> </li> <li>Moderate or severe acute illness with or without fever </li> </ul> </td> </tr> <tr> <td class="subtitle1_left" colspan="3">Tdap may be given to children with the following conditions that are incorrectly perceived as contraindications or precautions to Tdap</td> </tr> <tr> <td class="indent1" colspan="3"> <ul> <li>Fever of ≥40.5°C (105°F) for &lt;48 hours after vaccination with a previous dose of DTaP or DTwP </li> <li>History of collapse or shock-like state (ie, hypotonic hyporesponsive episode) within 48 hours after receiving a previous dose of DTaP or DTwP </li> <li>History of seizure with or without fever within 3 days after receiving a previous dose of DTaP or DTwP </li> <li>History of persistent, inconsolable crying lasting &gt;3 hours within 48 hours after receiving a previous dose of DTaP or DTwP </li> <li>History of extensive limb swelling after DTaP, DTwP, or Td that is not an Arthus-type reaction </li> <li>Stable or resolved neurologic disorder, including well-controlled seizures, history of seizure disorder, and cerebral palsy </li> <li>History of brachial neuritis </li> <li>Breastfeeding an infant </li> <li>Immunosuppression </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">Tdap: tetanus and reduced diphtheria toxoids, and acellular pertussis; 
	DTwP: diphtheria and tetanus toxoids, and whole-cell pertussis; 
	DTaP: diphtheria and tetanus toxoids, and acellular pertussis; 
	Td: tetanus and reduced diphtheria toxoids (adult Td, dT).<br/>
	
	* Precautions are conditions that may increase the risk for a serious reaction to immunization, cause diagnostic confusion, or compromise the ability of the vaccine to produce immunity. Although immunization is generally deferred in children and adolescents with precautions, decisions regarding administering diphtheria toxoid, tetanus toxoid, and pertussis-containing vaccines to children with precautions should be individualized according the benefits and risks, and reassessed at subsequent immunization visits.<br/>
	
	¶ Information about latex is available in the prescribing information, available from <a href="https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm" target="_blank">the US Food and Drug Administration</a>.</div><div class="graphic_reference">References:
	<ol>
<li>Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2018; 67:1.</li>
<li>Kroger AT, Bahta L, Hunter P. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Contraindications and precautions. Available at: <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html</a> (Accessed on January 19, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 79169 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
